Adocia SA - ESG Rating & Company Profile powered by AI
If you work at Adocia SA and you would like to licence your Sustainability aseessment, please contact us. This Disclosure score includes 17 UN Sustainable Development Goals including: 'Gender Equality', 'Climate Action' and 'Partnerships for the Goals'. This assessment of Adocia SA was prepared by All Street Sevva using advanced machine learning.
Adocia SA in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 8.0; made up of an environmental score of 8.0, social score of 8.0 and governance score of 8.0.
8.0
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Adocia SA | 8.0 | High |
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Adocia SA have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Adocia SA disclose current and historical energy intensity?
Sign up for free to unlockDoes Adocia SA report the average age of the workforce?
Sign up for free to unlockDoes Adocia SA reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Adocia SA disclose its ethnicity pay gap?
Sign up for free to unlockDoes Adocia SA disclose cybersecurity risks?
Sign up for free to unlockDoes Adocia SA offer flexible work?
Sign up for free to unlockDoes Adocia SA have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Adocia SA disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Adocia SA conduct supply chain audits?
Sign up for free to unlockDoes Adocia SA disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Adocia SA conduct 360 degree staff reviews?
Sign up for free to unlockDoes Adocia SA disclose the individual responsible for D&I?
Sign up for free to unlockDoes Adocia SA disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Adocia SA disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Adocia SA disclose water use targets?
Sign up for free to unlockDoes Adocia SA have careers partnerships with academic institutions?
Sign up for free to unlockDid Adocia SA have a product recall in the last two years?
Sign up for free to unlockDoes Adocia SA disclose incidents of discrimination?
Sign up for free to unlockDoes Adocia SA allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Adocia SA issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Adocia SA disclose parental leave metrics?
Sign up for free to unlockDoes Adocia SA disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Adocia SA disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Adocia SA disclose the pay ratio of women to men?
Sign up for free to unlockDoes Adocia SA support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Adocia SA disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Adocia SA reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Adocia SA involved in embryonic stem cell research?
Sign up for free to unlockDoes Adocia SA disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Adocia SA disclose its waste policy?
Sign up for free to unlockDoes Adocia SA report according to TCFD requirements?
Sign up for free to unlockDoes Adocia SA disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Adocia SA disclose energy use targets?
Sign up for free to unlockDoes Adocia SA disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Adocia SA have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Adocia SA
These potential risks are based on the size, segment and geographies of the company.
Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform is designed and developed to optimize the performance of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes bi-hormonal products, which include BioChaperone AsPram, which is a combination of rapid insulin aspart with pramlintide; and BioChaperone Glargine Liraglutidea, which is a fixed combination of insulin glargine with an analogue of the GLP-1 receptor. In addition, the company's preclinical pipeline includes multihormonal products for the treatment of obesity, including BioChaperone GluExe, which is a combination of glucagon and exenatide; PramExe, which is a combination of pramlintide and exenatide; and BioChaperone PramGluExe, which is a triple combination of pramlintide, glucagon and exenatide. It has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. The company was incorporated in 2005 and is headquartered in Lyon, France.